These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31012549)

  • 21. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
    Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
    Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
    Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
    Uckun FM; Qazi S; Dibirdik I; Myers DE
    Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
    Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
    Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.
    Barta SK; Zou Y; Schindler J; Shenoy N; Bhagat TD; Steidl U; Verma A
    Leuk Lymphoma; 2012 Oct; 53(10):1999-2003. PubMed ID: 22448921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
    Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
    Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
    J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
    Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
    Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia.
    Tatar AS; Jurj A; Tomuleasa C; Florea A; Berindan-Neagoe I; Cialla-May D; Popp J; Astilean S; Boca S
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110478. PubMed ID: 31541890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
    Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M
    Ann Hematol; 2014 Mar; 93(3):485-492. PubMed ID: 24154679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The expression of CD19 in 210 cases of childhood acute leukemia and its significance].
    Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
    Zhonghua Er Ke Za Zhi; 2004 Mar; 42(3):188-91. PubMed ID: 15144712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.
    Seidel UJ; Schlegel P; Grosse-Hovest L; Hofmann M; Aulwurm S; Pyz E; Schuster FR; Meisel R; Ebinger M; Feuchtinger T; Teltschik HM; Witte KE; Schwarze CP; Rammensee HG; Handgretinger R; Jung G; Lang P
    Mol Ther; 2016 Sep; 24(9):1634-43. PubMed ID: 27380762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
    Yoshida S; Tuscano E; Duong C; Chung J; Li Y; Beckett L; Tuscano JM; Satake N
    Leuk Lymphoma; 2017 May; 58(5):1254-1257. PubMed ID: 27701909
    [No Abstract]   [Full Text] [Related]  

  • 39. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
    Rayes A; McMasters RL; O'Brien MM
    Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
    Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
    Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.